Recurrent SPOP mutations in prostate cancer

Patent metadata

Field	Value
Publication number	US-10443102-B2
Application number	US-201214000484-A
Country	US
Kind code	B2
Filing date	Feb 9, 2012
Priority date	Feb 24, 2011
Publication date	Oct 15, 2019
Grant date	Oct 15, 2019

Abstract

The invention relates generally to new prostate cancer markers, and particularly to a class of cancer marked by the presence of missense mutations in SPOP, an E3 ubiquitin ligase component. The invention provides methods and materials for detecting and diagnosing prostate cancer by detecting these mutations and may be useful in predicting disease progression and response to therapy.

First claim

We claim:

1. A method comprising detecting a SPOP mutation in a prostate sample using a nucleic acid-based assay, wherein said SPOP mutation is a missense mutation at an amino acid position that is in the MATH domain of SPOP and responsible for substrate binding selected from the group consisting of Y87, F102, 5119, K129, W131, and K134.

2. The method of claim 1 , wherein said prostate sample is prostate tissue, urine, semen, a prostatic secretion, or prostate cells.

3. The method of claim 1 , wherein the SPOP mutation is detected by (a) amplifying nucleic acid comprising SPOP in said prostate sample, and (b) sequencing the amplified nucleic acid to identify the presence of a mutation.

4. The method of claim 3 , wherein said amplifying comprises amplifying the MATH domain of SPOP.

5. The method of claim 1 , which comprises detecting said mutation in situ.

6. The method of claim 1 , which comprises obtaining nucleic acid from said prostate sample and detecting a SPOP mutation by a microarray-based assay or by an RT-PCR-based assay.

7. The method of claim 1 which further comprises detecting the presence or absence of one or more co-occurring genomic alterations.

8. The method of claim 7 wherein said genomic alterations are selected from the group consisting of the absence of a PTEN mutation or the absence of PTEN copy number loss.

9. The method of claim 8 wherein said genomic alterations are the presence of a 5q21 deletion, the presence of a 6q21 deletion or the absence of an ETS-rearrangement, or any combination thereof.

10. The method of claim 7 , wherein said prostate sample is prostate tissue, urine, semen, a prostatic secretion or prostate cells.

11. The method of claim 1 , wherein the SPOP mutation is selected from the group consisting of S119N, K134N, Y87N, W131G, K129E, and F102C.

12. A method comprising detecting a SPOP mutation in a prostate sample using a nucleic acid-based assay, wherein said SPOP mutation is a missense mutation at the amino acid position F133 that is in the MATH domain of SPOP and responsible for substrate binding.

13. The method of claim 12 , wherein said prostate sample comprises prostate tissue or prostate cells.

14. The method of claim 12 , wherein the SPOP mutation is detected by (a) amplifying nucleic acid comprising SPOP in said prostate sample, and (b) sequencing the amplified nucleic acid to identify the presence of a mutation.

15. The method of claim 14 , wherein said amplifying comprises amplifying the MATH domain of SPOP.

16. The method of claim 12 , which comprises obtaining nucleic acid from said prostate sample and detecting a SPOP mutation by a microarray-based assay.

17. The method of claim 12 which further comprises detecting the presence or absence of one or more co-occurring genomic alterations.

18. The method of claim 17 , wherein said genomic alterations are selected from the group consisting of the absence of a PTEN mutation or the absence of PTEN copy number loss.

19. The method of claim 17 , wherein said genomic alterations comprise the absence of an ETS-rearrangement.

20. The method of claim 17 , wherein said prostate sample is prostate tissue.

21. The method of claim 12 , wherein the missense mutation is F133V.

Assignees

• Rubin Mark A
• Barbieri Christopher
• Univ Cornell

Inventors

• Rubin Mark A
• Barbieri Christopher

Classifications

• G01N33/57555

  of the prostate · CPC title

• G01N33/5758

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• C12Q2600/112

  Disease subtyping, staging or classification · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title